Table 3.

Interim report for phase III trial on 741 mild COVID-19 patients published by Hetero.

Significant early clinical improvement in Molnupiravir treatment group in comparison to standard care on days 5, 10 and 14 with 2-point reduction in WHO Clinical Progression Scale
Day	Molnupiravir vs Standard Care	P value
Day 5	63.43% vs 22.33%	p=<0.0001
Day 10	78.96% vs 49.49%	p=<0.0001
Day 14	81.55% vs 73.22%	p = 0.0150
Clinical improvement median time in Molnupiravir was at 8 days while Standard of Care was at 12 days (p = 0.0001)
Less hospitalization was observed in Molnupiravir group vs SOC over 14 days (7 (1.89%) vs 23 (6.22%), p = 0.0027)
Negativity of SARS CoV-2 RT-PCR was early observed in Molnupiravir group in comparison to standard of care
Day	Molnupiravir vs Standard Care	P value
Day 5	77.35% vs 26.07%	p=<0.0001
Day 10	94.03% vs 57.20%	p=<0.0001
Day 14	97.01% vs 85.21%	p=<0.0001
No mortality was reported in both groups